Ciencias Médicas Básicas
Departamento
![Foto de Juan Carlos](/img/nophoto.png)
Juan Carlos
Kaski
Publicaciones en las que colabora con Juan Carlos Kaski (22)
2012
-
Anti-inflammatory effects of ivabradine in patients with acute coronary syndrome: A pilot study
International Journal of Cardiology, Vol. 158, Núm. 1, pp. 160-162
-
Cardiopulmonary exercise testing for the assessment of exercise capacity in patients with cardiac syndrome X
International Journal of Cardiology, Vol. 154, Núm. 1, pp. 85-87
-
Usefulness of serum neopterin levels in acute decompensated heart failure to predict renal dysfunction
Biomarkers, Vol. 17, Núm. 2, pp. 134-139
2010
-
Diurnal variation of circulating myeloperoxidase levels in patients with ST-segment elevation myocardial infarction
International Journal of Cardiology, Vol. 144, Núm. 3, pp. 407-409
-
Elevated circulating soluble form of CD40 ligand in patients with cardiac syndrome X
Atherosclerosis, Vol. 213, Núm. 2, pp. 637-641
-
Melatonin and circadian biology in human cardiovascular disease
Journal of Pineal Research, Vol. 49, Núm. 1, pp. 14-22
-
Neopterin predicts left ventricular remodeling in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
Atherosclerosis, Vol. 211, Núm. 2, pp. 574-578
-
Usefulness of intraplatelet melatonin levels to predict angiographic no-reflow after primary percutaneous coronary intervention in patients with st-segment elevation myocardial infarction
American Journal of Cardiology, Vol. 106, Núm. 11, pp. 1540-1544
2009
-
Disruption of normal circadian rhythms and cardiovascular events
Heart and Metabolism, pp. 11-15
-
Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation
Thrombosis Research, Vol. 123, Núm. 4, pp. 617-621
-
Inflammatory systemic biomarkers in setting acute coronary syndromes - Effects of the diurnal variation
Current Drug Targets, Vol. 10, Núm. 10, pp. 1001-1008
-
Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention-Effects on soluble CD40 ligand concentrations
Atherosclerosis, Vol. 206, Núm. 2, pp. 523-527
-
Melatonina y aterosclerosis coronaria
Clinica e Investigacion en Arteriosclerosis, Vol. 21, Núm. 5, pp. 247-256
-
Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: Effects of the i f current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome-RIVIERA trial study design and rationale
Cardiovascular Drugs and Therapy, Vol. 23, Núm. 3, pp. 243-247
-
Role of ischemia modified albumin to ST-segment resolution after mechanical reperfusion in patients with ST-segment elevation myocardial infarction
Atherosclerosis, Vol. 203, Núm. 2, pp. 576-580
2008
-
Association of ischemia-modified albumin and melatonin in patients with ST-elevation myocardial infarction
Atherosclerosis, Vol. 199, Núm. 1, pp. 73-78
-
High serum matrix metalloproteinase-9 level predict increased risk of in-hospital cardiac events in patients with type 2 diabetes and ST segment elevation myocardial infarction
Atherosclerosis, Vol. 196, Núm. 1, pp. 365-371
-
Light/dark patterns of soluble vascular cell adhesion molecule-1 in relation to melatonin in patients with ST-segment elevation myocardial infarction
Journal of Pineal Research, Vol. 44, Núm. 1, pp. 65-69
-
Prognostic Value of Admission Myeloperoxidase Levels in Patients With ST-Segment Elevation Myocardial Infarction and Cardiogenic Shock
American Journal of Cardiology, Vol. 101, Núm. 11, pp. 1537-1540
-
Relation of ischemia-modified albumin levels and left ventricular systolic function in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention
Clinica Chimica Acta, Vol. 388, Núm. 1-2, pp. 196-199